Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1
CIN
Cisplatin resistance
IDO1/Kyn/AhR/IL-6
Navoximod
OSCC
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
received:
31
08
2023
revised:
27
10
2023
accepted:
31
10
2023
medline:
4
12
2023
pubmed:
10
11
2023
entrez:
9
11
2023
Statut:
ppublish
Résumé
Oral squamous cell carcinoma (OSCC) is the most prevalent aggressive form of HNSC and treated with platinum-based chemotherapy as initial therapy. However, the development of acquired resistance and neurotoxicity to platinum agents poses a significant challenge to treat locally advanced OSCC. Notably, IDO1
Identifiants
pubmed: 37944638
pii: S0024-3205(23)00874-3
doi: 10.1016/j.lfs.2023.122239
pii:
doi:
Substances chimiques
Kynurenine
343-65-7
Cisplatin
Q20Q21Q62J
navoximod
926SHL95NC
Interleukin-6
0
Receptors, Aryl Hydrocarbon
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122239Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.